CD38 and Miyoshi myopathy: Treatment of multiple myeloma (MM) has advanced with the development of novel agents, including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies, resulting in significant improvements in the long-term prognosis of patients with MM.